Search

Your search keyword '"Rossi, Antonella Russo"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Rossi, Antonella Russo" Remove constraint Author: "Rossi, Antonella Russo" Database ScienceDirect Remove constraint Database: ScienceDirect
28 results on '"Rossi, Antonella Russo"'

Search Results

2. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

4. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

6. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

7. Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the ‘NEXT-IN-CML' Study

9. 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party

12. Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment

13. Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (

14. Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival

15. APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS

16. Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy

18. Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML

19. Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs

20. Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients

21. Imatinib In Very Elderly CML Patients: What Can We Achieve?.

23. Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.

24. BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

25. CXCR4 as a Predictor of Response in Acute Myeloid Leukemia

Catalog

Books, media, physical & digital resources